Intravenous treosulfan versus intravenous treosulfan plus cisplatinum in advanced ovarian carcinoma

Publisher Website
Google Scholar
Abstract
In a prospective, multicentre, randomized trial, the efficacy and toelrance of treosulfan alone was compared with that of tresulfan plus cisplatinum in 135 women with advanced ovarian sarcinoma. No statistically significant difference was found between the two treatments in terms of median survival. Combined treatment was associated with significantly greater side-effects and haematological toxicity. Optimal survival with minimal toxicity can be achieved by using treosulfan alone in patients (mainly stages Ic or II) with minimal postoperative residual disease. Patients (likely to be stage III or IV) with greater residual disease should receive treosulfan plus cisplatinum.